Terlipressin: Current and emerging indications in chronic liver disease

J Gastroenterol Hepatol. 2018 Mar;33(3):591-598. doi: 10.1111/jgh.14009.

Abstract

Terlipressin is an analogue of vasopressin that has potent vasoactive properties and has been available for use in most countries for nearly two decades. It has both established roles and emerging indications in the management of complications of decompensated chronic liver disease. We explore historic and emerging literature regarding the use of terlipressin for a range of indications including hepatorenal syndrome, portal hypertensive bleeding, and disruptions in sodium homeostasis. Novel methods of infusion-based terlipressin administration including the beneficial effect in reduction of adverse events are explored, in addition to new indications for the use of terlipressin in decompensated cirrhosis in an outpatient setting.

Keywords: cirrhosis; hepatorenal syndrome; portal hypertension; terlipressin.

Publication types

  • Review

MeSH terms

  • Chronic Disease
  • Humans
  • Infusions, Intravenous
  • Liver Circulation / drug effects
  • Liver Cirrhosis / drug therapy
  • Liver Cirrhosis / physiopathology
  • Liver Diseases / drug therapy*
  • Liver Diseases / physiopathology
  • Lypressin / administration & dosage
  • Lypressin / analogs & derivatives*
  • Lypressin / pharmacology
  • Portal Pressure / drug effects
  • Renal Circulation / drug effects
  • Terlipressin

Substances

  • Lypressin
  • Terlipressin